Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210315951CANCER THERAPY BY COMBINATION USE OF ONCOLYTIC VACCINIA VIRUS AND IMMUNE CHECKPOINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINATION MEDICINE FOR USE IN THE CANCER THERAPY
US 14.10.2021
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
Appl.No 17279937 Applicant ASTELLAS PHARMA INC. Inventor Shinsuke NAKAO

The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.

2.20210315838SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION
US 14.10.2021
Int.Class A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
Appl.No 17301188 Applicant Applied Biology, Inc. Inventor Ofer A. Goren

The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-β inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

3.20210317466EXPRESSION OF UNFOLDED PROTEIN RESPONSE PROTEINS IMPROVES PLANT BIOMASS AND GROWTH
US 14.10.2021
Int.Class C12N 15/82
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
Appl.No 17051683 Applicant Board of Trustees of Michigan State University Inventor Federica Brandizzi

Described herein are expression cassettes, plant cells, plant seeds, plants, and methods useful for improving the glucan content and growth of plants.

4.20210317170COMPOSITIONS AND METHODS FOR DRUG DELIVERY AND TREATING VIRAL INFECTIONS
US 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17086957 Applicant UT-Battelle, LLC Inventor Joseph Christopher Ellis

The present disclosure is directed to compositions and methods for targeted drug delivery that comprise a biocompatible framework carrying at least one drug and a viral surface protein, where the viral surface protein mediates entry into a target cell and is attached to an outer surface of the biocompatible framework in the drug carrier.

5.WO/2021/203198COMPOSITIONS AND METHODS FOR TREATMENT OF CORONAVIRIDAE INFECTIONS
WO 14.10.2021
Int.Class A61K 38/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
50acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
Appl.No PCT/CA2021/050462 Applicant PICCHIO INTERNATIONAL INC. Inventor BELLINI, Francesco
The present technology generally relates to the use of an asparaginase compound, and optionally of a chloroquine active agent and/or a serine protease inhibitor and/or a lectin, for inhibiting or treating a Coronaviridae infection in a subject.
6.WO/2021/204338PRODUCTION OF GERANYL DIPHOSPHATE-DERIVED COMPOUNDS
WO 14.10.2021
Int.Class C12N 9/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
02Oxidoreductases (1.), e.g. luciferase
04acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
Appl.No PCT/DK2021/050098 Applicant KØBENHAVNS UNIVERSITET Inventor KAMPRANIS, Sotirios
Disclosed is yeast cells having peroxisomally localized GPP synthase and a peroxisomally localized enzyme that converts GPP into a monoterpenoids, cannabinoids, monoterpene indole alkaloids and prenylated aromatic compounds; or a precursor therefore, which yeast cells are capable of producing improved amounts of monoterpenoids, cannabinoids, monoterpene indole alkaloids and prenylated aromatic compounds, compared with the same yeast cells where the GPP synthase and the enzyme that converts GPP are located in the cytoplasm. Further disclosed is the use of the yeast cell for producing monoterpenoids, cannabinoids, monoterpene indole alkaloids and prenylated aromatic compounds.
7.WO/2021/205208DEVICE FOR NORMALIZING HUMAN CELL GENE EXPRESSION AND WEAKENING CORONAVIRUS GENE EXPRESSION USING MAGNETIC AND ELECTROMAGNETIC FIELDS
WO 14.10.2021
Int.Class A61N 2/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
2Magnetotherapy
02using magnetic fields produced by coils, including single turn loops or electromagnets
Appl.No PCT/IB2020/053348 Applicant HASHEMI, Ali Inventor HASHEMI, Ali
The invention of device for normalizing human cell gene expression and weakening coronavirus gene expression using magnetic and electromagnetic fields which by making magnetic field and controlling the intensity, direction and wave length using servomotors, supports and electromagnetic wave generation module can make some changes in gene expression of viruses like corona to prevent from propagation and spread of virus. Also the magnetic field by making some natural changes in gene expression of human cells cause to indispose the environment for the propagation and growth of viruses and as a result cause the virus to be semi active. This magnetic field allows to treat the diseases with metabolic, bacterial, microbial and genetically origins.
8.WO/2021/206183FUNCTIONAL POLYPEPTIDES AND USE THEREOF
WO 14.10.2021
Int.Class C12N 15/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
Appl.No PCT/JP2021/015369 Applicant NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY Inventor SAKAI, Ryuichi
A polypeptide that comprises the amino acid sequence of SEQ ID NO: 1 and has a function of delivering a substance into cells, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2 and has a function of degrading a nucleic acid molecule, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 3 and has a function of degrading a nucleic acid molecule and a function of intranuclearly migrating the same, polynucleotides encoding the respective polypeptides, and transformed cells containing the respective polynucleotides.
9.WO/2021/206303METHOD FOR PREPARING ANIMAL TISSUE-DERIVED BIOMATERIAL, ANIMAL TISSUE-DERIVED BIOMATERIAL PREPARED THEREBY, AND 3D PRINTING METHOD USING SAME
WO 14.10.2021
Int.Class A61L 27/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
27Materials for prostheses or for coating prostheses
36containing ingredients of undetermined constitution or reaction products thereof
Appl.No PCT/KR2021/003273 Applicant T&R BIOFAB CO., LTD. Inventor KIM, Hyun Jung
The present invention relates to a method for preparing an animal tissue-derived biomaterial, an animal tissue-derived biomaterial prepared thereby, and a 3D printing method using same, the method for preparing an animal tissue-derived biomaterial comprising: a decellularizing step of removing cells from a tissue; a liquefying step of liquefying the extracellular matrix of the decellularized tissue by means of an acid protease; a filtering step of filtering a decellularized extracellular matrix solution obtained from the liquefying step; and a sterilizing step of sterilizing a mixture obtained from the filtering step. The animal tissue-derived biomaterial of the present invention exhibits excellent biocompatibility and storage stability.
10.WO/2021/206513PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO 14.10.2021
Int.Class C07C 215/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
215Compounds containing amino and hydroxy groups bound to the same carbon skeleton
46having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
48with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
54linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
Appl.No PCT/KR2021/004523 Applicant KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY Inventor KWON, Ki-Sun
The present invention relates to a pharmaceutical composition for preventing or treating muscular weakness-related diseases, comprising alverine, 4-hydroxy alverine, a derivative thereof, or a pharmaceutically acceptable salt thereof. When myoblasts are treated with the alverine, 4-hydroxy alverine, derivative thereof, or pharmaceutically acceptable salt thereof of the present invention, differentiation into myotubes is promoted. Therefore, the alverine, 4-hydroxy alverine, derivative thereof, or pharmaceutically acceptable salt thereof according to the present invention can be effectively used in the promotion of differentiation of myoblasts and the prevention or treatment of muscular weakness-related diseases.